4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one | 1383377-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one
• 英文别名: 4-[3-(4-fluorophenyl)-1-methylpyrazol-4-yl]-6-(oxan-4-yl)-7H-pyrrolo[3,4-b]pyridin-5-one
• CAS: 1383377-27-2
• 化学式: C₂₂H₂₁FN₄O₂
• 分子量: 392.433
• InChiKey: YCUSKMMSBMJKNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  60.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS
  申请人：BUTLER TODD W.

  公开号：US20120157440A1

  公开（公告）日：2012-06-21

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, A, R 4 , n, and R 7 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药用可接受的盐，其中该化合物具有Formula I的结构：以及其药用可接受的盐，其中X、Y、A、R4、n和R7如规范中定义。本发明还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION
  申请人：Facio Intellectual Property B.V.

  公开号：EP3498278A1

  公开（公告）日：2019-06-19

  The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, in this case facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及用于治疗与 DUX4 表达有关的疾病的化合物，例如肌肉萎缩症，在本例中为面肩肱肌萎缩症（FSHD）。本发明还涉及此类化合物的用途或使用方法。
• Compounds for treatment of diseases related to DUX4 expression
  申请人：Facio Intellectual Property B.V.

  公开号：US10973820B2

  公开（公告）日：2021-04-13

  The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及用于治疗与DUX4表达有关的疾病的化合物，如肌肉萎缩症，其中该疾病为面肩肱肌营养不良症（FSHD）。本发明还涉及此类化合物的用途或使用方法。
• US8536164B2
  申请人：——

  公开号：US8536164B2

  公开（公告）日：2013-09-17
• [EN] CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER<br/>[FR] INHIBITEURS DE LA CASÉINE KINASE 1 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES LIÉES À L'EXPRESSION DE DUX4 TELLES QUE LA DYSTROPHIE MUSCULAIRE ET LE CANCER
  申请人：FACIO INTELLECTUAL PROPERTY B V

  公开号：WO2020249717A1

  公开（公告）日：2020-12-17

  The present invention relates to casein kinase 1 inhibitors alone or in combination with p38 inhibitors for use in the treatment of diseases related to DUX4 expression, such as muscular dystrophies and cancer.